| Autor: |
Shu, Sahara, Mitsushige, Sugimoto, Hitomi, Ichikawa, Takuma, Kagami, Yukitoshi, Sakao, Naro, Ohashi, Yoshiaki, Horio, Ken, Sugimoto, Akihiko, Kato, Takahisa, Furuta, Hideo, Yasuda |
| Rok vydání: |
2017 |
| Předmět: |
|
| Zdroj: |
Digestion. 97(2) |
| ISSN: |
1421-9867 |
| Popis: |
An optimum Helicobacter pylori-eradication regimen for hemodialysis patients is yet to be established because of different pharmacokinetics of amoxicillin involved between hemodialysis patients and healthy subjects. We investigated to establish appropriate doses of amoxicillin for H. pylori infection eradication in hemodialysis patients.Of 409 hemodialysis patients screened for H. pylori infection, 37 H. pylori-positive patients were randomized to different 1-week eradication regimens: esomeprazole 20 mg twice a day (b.i.d.) and clarithromycin 200 mg b.i.d., plus amoxicillin at either 750 mg b.i.d. (group A; conventional) or 250 mg b.i.d. (group B; experimental). Sixty-three patients with normal renal function received the conventional regimen (group C). Successful eradication was confirmed by urea breath testing.Eradication rates of group B (reduced amoxicillin-regimen) were 84.2% in intention-to-treat analysis and 88.9% in per-protocol analysis, which were similar with group A (77.8 and 77.8%) and group C (74.6 and 81.0%). However, the incidence of adverse events in group A was significantly higher than that in group C (22.2 vs. 5.1%, p = 0.027).In H. pylori-positive hemodialysis patients, amoxicillin at 250 mg b.i.d. may be an appropriate scheme for eradication with equivalent effects to the conventional therapy and safety effects for adverse events. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
